Cystic Fibrosis Liver Disease
10
1
2
6
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 10 trials
100.0%
+13.5% vs benchmark
10%
1 trials in Phase 3/4
0%
0 of 6 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 6 completed trials
Clinical Trials (10)
VALidation of Imaging-based Liver Biomarkers in PEDiatric Patients
MRI to Characterize and Predict CF Liver Disease in PUSH Cohort
Longitudinal Assessment of Transient Elastography in Cystic Fibrosis
Real World Clinical Outcomes With Novel Modulator Therapy Combinations in People With CF (RECOVER)
The Use of Novel Diagnostic Tools to Increase Detection of Early Fibrosis in Cystic Fibrosis Related Liver Disease to Improve Clinical Management
Relationship Between the Development of Impaired Glucose Tolerance, the Phenotype of CFLD, and the Risk of Liver Fibrosis
Glycemic Characterization and Pancreatic Imaging Correlates in Cystic Fibrosis
Pre-emptive Transjugular Intrahepatic Portosystemic Shunt (TIPS) in Cystic Fibrosis Related Liver Disease
Examination of the Lipid Metabolism of the Liver After Choline Substitution in Cystic Fibrosis
Utility of Point Shear-wave Elastography to Assess for Hepatic & Pancreatic Fibrosis in Pediatric CF Patients